Introduction {#sec1}
============

Glaucoma is an optic neuropathy caused by apoptosis of retinal ganglion cells that leads to visual field loss and eventually to blindness.[@bib1] A combination of genetic predisposition, immune system alterations, and stress factors is believed to contribute to the pathogenesis of glaucoma,[@bib2] which is now considered a neurodegenerative syndrome rather than simply an eye disease.

Recent evidence indicates that neurodegenerative lesions in glaucoma extend to the retina, intracranial optic nerve, lateral geniculate body, and visual cortex. In the lateral geniculate nucleus (LGN), apoptosis is characterized by neuronal shrinkage and is accompanied by glial activation and a decreased thickness of both LGN and visual cortex.[@bib3]^,^[@bib4]

Glaucoma shares some features with Alzheimer\'s disease (AD), such as age-related incidence, apoptosis of specific neuronal populations, protein misfolding, production of reactive oxygen species, and vascular abnormalities.[@bib5]^,^[@bib6] Remarkably, optic nerve degeneration and apoptosis of retinal ganglion cells have been described in AD patients,[@bib7]^,^[@bib8] but the existence of a pathogenic link between glaucoma and AD, if any, remains to be elucidated.

One of the key hallmarks of AD is the progressive accumulation of amyloid-β (Aβ) peptides in the brain, particularly in the frontal, parietal, and temporal cortices. Recently, the presence of Aβ peptides has also been reported in the retina of AD patients.[@bib9] Additionally, Aβ peptides and other AD-related proteins were found in the aqueous humor (AH) of patients affected by glaucoma and pseudoexfoliation syndrome, suggesting Aβ as a possible common etiologic factor for AD and glaucoma.[@bib10]^,^[@bib11] To further investigate this issue, we analyzed the AH concentration of Aβ~42~, the most toxic Aβ species, in glaucomatous and control patients undergoing ocular surgery.

Methods {#sec2}
=======

Research Design and Participants {#sec2-1}
--------------------------------

From April to October 2018, 81 candidates for cataract or glaucoma surgery were consecutively enrolled according to the criteria set by the Declaration of Helsinki. Thirty-two males and 49 females (median age, 77 years) who were attending the University Eye Clinic of Genoa to undergo ocular surgery were grouped according to the presence of glaucoma. Thirty-two subjects (12 males and 20 females) were affected by glaucoma, including primary open-angle glaucoma, secondary open-angle glaucoma (pseudo-exfoliative glaucoma, pigmentary glaucoma), or primary closed-angle glaucoma; 49 patients were glaucoma free (20 control males and 29 control females). Two patients with glaucoma and three control subjects underwent surgery in both eyes, but only one eye was randomly selected for the statistical analysis. The institutional review board of the Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health at the University of Genoa approved this study. All patients signed the informed consent form.

Clinical Procedures {#sec2-2}
-------------------

Detailed medical, pharmacological, and ocular histories of patients were obtained and recorded. Before surgery, all patients underwent ophthalmological examinations that included fundus photography, best-corrected visual acuity measurement, slit-lamp biomicroscopy, and intraocular pressure (IOP) measurement with Goldmann applanation tonometry. In glaucomatous patients, visual field indices were recorded when feasible. Biometry was performed with a Nidek AL-Scan (Aichi, Japan) and Haag-Streit Lenstar LS900 (Köniz, Switzerland). Axial length (AXL), anterior chamber depth (ACD), and central corneal thickness (CCT) were recorded. All patients underwent optical coherence tomography (OCT) examination (unless not possible due to media opacities), and ganglion cell complex (GCC) and retinal nerve fiber layer (RNFL) mean thickness analyses were conducted using an Optovue RTVue RT-100 (Fremont, CA). During the procedure of cataract or glaucoma surgery, an AH sample was collected and immediately processed for total protein (TP) and Aβ~42~ analyses.

Aβ~42~ Evaluation {#sec2-3}
-----------------

Because Aβ peptides undergo temperature- and time-dependent aggregation changes that may interfere with their quantitative evaluation, fresh samples of AH underwent specific Aβ~42~ highly sensitive enzyme-linked immunosorbent assay (ELISA; Waco Human/Rat β Amyloid(42), Fujifilm, Tokyo, Japan) immediately upon collection. ELISA analyses were carried out following the manufacturer\'s protocol, and the levels of Aβ~42~ peptides were calculated according to the standard curves prepared on the same ELISA plates.

Total Protein Measurement {#sec2-4}
-------------------------

TP concentrations were analyzed in freshly collected AH samples using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA), according to the manufacturer\'s instructions.

Data Analysis {#sec2-5}
-------------

All data are expressed as mean ± SD. Statistical analysis was performed using SPSS Statistics 21.0 (IBM, Armonk, NY). Differences between the control and glaucomatous groups were evaluated with unpaired *t*-tests. Pearson\'s correlation was used to measure the strength of linear association between Aβ~42~ levels and the other tested parameters. Statistical significance was set at *P* \< 0.05.

Results {#sec3}
=======

The glaucoma and control groups were homogeneous for gender and age ([Fig.](#fig1){ref-type="fig"} A). A significant increase in TP concentration (+20%; *P* = 0.02) was found in the AH of glaucoma patients compared with control samples ([Fig.](#fig1){ref-type="fig"} B). Particularly, such increases were greater within the glaucomatous female group when compared to both female controls (+27%; *P* = 0.010) and male controls (+32%; *P* = 0.038) ([Fig.](#fig1){ref-type="fig"} C). A moderate positive correlation was observed either between TP concentration and Aβ~42~ levels (*r* = 0.51; *P* \< 0.0001) ([Fig.](#fig1){ref-type="fig"} D) or between TP concentration and pre-operative IOP (*r* = 0.44; *P* \< 0.0001) ([Fig.](#fig1){ref-type="fig"} E).
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Pre-operative IOP was slightly higher in glaucomatous patients than in controls (+16%; *P* \< 0.01), despite anti-glaucoma medications not being discontinued ([Table 1](#tbl1){ref-type="table"}). As expected,[@bib12] a significant reduction in terms of OCT GCC (--17%; *P* \< 0.001), OCT RNFL (--19%; *P* \< 0.05), AXL (--3%; *P* \< 0.05), and CCT (--5%; *P* \< 0.01) was detected in the glaucomatous group of patients compared to controls, whereas no differences were measured in terms of AH Aβ~42~ concentration and ACD ([Table 1](#tbl1){ref-type="table"}).

###### 

Differences Between Control and Glaucomatous Patients

  Analyzed Parameter       Control          Glaucoma         *P*
  ------------------------ ---------------- ---------------- ------------
  AH Aβ~42~, pg/ml         47.19 ± 20.21    53.33 ± 23.21    0.211
  IOP, mm Hg               15.20 ± 2.74     17.67 ± 4.58     **0.006**
  OCT GCC, µm              88.65 ± 9.67     73.74 ± 12.10    **0.0002**
  OCT RNFL (overall), µm   82.59 ± 12.69    67.18 ± 14.23    **0.032**
  AXL, mm                  23.89 ± 1.57     23.20 ± 0.57     **0.026**
  ACD, mm                  3.13 ± 0.33      3.27 ± 0.33      0.211
  CCT, µm                  555.10 ± 31.61   527.40 ± 37.87   **0.003**

Data are expressed as mean ± SD. Statistical analysis was performed with unpaired *t*-tests. Bold means statistically significant values.

In line with the results indicating a relationship between TP and Aβ~42~ and between TP and pre-operative IOP, levels of AH Aβ~42~ were found to increase with increasing IOP (*r* = 0.222; *P* = 0.033), whereas no correlation was observed between AH Aβ~42~ concentration and the other clinical parameters analyzed ([Table 2](#tbl2){ref-type="table"}).

###### 

Pearson\'s Correlation Between AH Aβ~42~ Levels and Clinical Variables

                *r*       *P*
  ------------- --------- -----------
  IOP           0.222     **0.033**
  OCT GCC       --0.026   0.102
  OCT RNFL      0.028     0.917
  ACD           0.163     0.173
  CCT           0.045     0.737
  Patient age   0.029     0.792

Discussion {#sec4}
==========

The AH is a clear transparent fluid that fills the anterior and posterior chamber of the eye. When produced by the ciliary processes in the posterior chamber, it flows through the pupil into the anterior chamber. This fluid delivers neurotransmitters and provides nutrients for the metabolism of the avascular cornea and lens. In addition, it removes waste products, allows drug distribution, and, during inflammation, carries inflammatory mediators and cells.[@bib13]

Samples of AH can be relatively easily collected from the anterior chamber and used for diagnostic and therapeutic purposes. Indeed, microbiological and molecular AH analyses are widely used for cases of infectious and inflammatory eye diseases. Moreover, proteomic studies have revealed that AH composition might change in ocular pathologies such as glaucoma, macular edema, and optic neuritis.[@bib14]^--^[@bib17]

AH Aβ peptides and other AD-related proteins can be found in the AH of patients with pseudoexfoliation syndrome and glaucoma, suggesting a common etiology for these diseases and implicating Aβ as a possible mutual therapeutic target.[@bib10]^,^[@bib11]^,^[@bib18] However, in line with studies performed by others,[@bib10]^,^[@bib19] our results did not show any statistically significant difference in terms of AH Aβ~42~ concentration between the glaucoma and control groups or with respect to other clinical parameters. Conversely, we found a significant increase of TP in the AH of glaucomatous patients, consistent with previous reports showing an increment of pro-inflammatory cytokine[@bib20]^--^[@bib23] and proteins related to the extracellular matrix remodeling[@bib24] in the AH of subjects affected by glaucoma. Interestingly, our results indicate that this increase in TP was greater within the female group of glaucomatous patients, although the lower number of male patients could have biased these results (12 male vs. 20 female glaucomatous AH samples). Nevertheless, there is evidence that hormonal factors and, in particular, variations in estrogen levels over the lifetime of a woman may play a pathogenic role in glaucoma.[@bib25] Indeed, Janciauskiene and colleagues[@bib10] found that women have significantly higher frequencies of detected inflammatory-related proteases in the AH compared to males, but whether female gender is a real risk factor for the ocular disease remains controversial. Certainly, there is an increased incidence of Alzheimer\'s disease cases in women compared to men, and this cannot simply depend on higher female longevity.[@bib26] Of note, in this context, we found a significant positive correlation between Aβ~42~ and TP concentration in AH samples ([Fig.](#fig1){ref-type="fig"} D), although the amyloidogenic peptide did not increase within the glaucomatous group. Even if we cannot yet exclude the suggestion that the increased TP in glaucomatous AH samples could be due to the increase of particular proteins, the number of specific proteins found to be augmented in glaucomatous AH would suggest the existence of a generic protein disequilibrium that may affect IOP.

In our study, pre-operative IOP was still slightly higher in glaucomatous patients, even if they did not stop anti-glaucoma treatments. Interestingly, a significant positive correlation was found between pre-operative IOP and TP concentration, further supporting the hypothesis that increased TP in AH may have a pathogenic role in glaucoma. Yet, from this point of view, the slight positive correlation found between pre-operative IOP and Aβ~42~ concentration ([Table 2](#tbl2){ref-type="table"}) could simply reflect the increase in TP.

On the other hand, the fact that all glaucomatous subjects were on pharmacological therapy represents a limitation in this study, and a validation of the observed phenomena in untreated glaucomatous patients would certainly allow a better understanding of their pathology.

In conclusion, although further studies on larger sample sizes are definitively needed, characterization of the AH protein profile in glaucomatous patients would help us to clarify whether the protein enhancement (1) represents a causative factor or is a disease consequence; (2) involves specific proteins, such as Aβ peptides; and (3) can be used as a marker of disease or as a novel therapeutic target.
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